Comparison of patient survival on adjuvant FOLFOX6 and XELOX chemotherapy after resection for gastric cancer / 中国肿瘤临床

ABSTRACT

Objective:To compare the survival of resected gastric cancer patient treated with oxaliplatin, 5-fluorouracil, and leu-covorin (FOLFOX6) with those treated with oxaliplatin and capecitabine (XELOX). Methods:A total of 147 resected gastric cancer pa-tients accepted the treatment. Among them, 99 were treated with FOLFOX6 and 48 were treated with XELOX. Adverse events and sur-vival rates of the two groups were compared. Results:Incidence of leukopenia and hepatic dysfunction in the FOLFOX6 group was sig-nificantly higher than that of the XELOX group (P0.05) between the two groups. After 1, 3, and 5 years, disease-free and overall survivals between the two groups were not significantly differ-ent (P>0.05). Conclusion:The effects of FOLFOX6 and XELOX adjuvant chemotherapies on long-term survival of resected gastric cancer patients were found to have no significant difference.